CETP Gene TaqIB: HDL/LDL Balance and Statin Interactions

CETP: The Lipid Exchange Enzyme

CETP is a plasma glycoprotein secreted primarily by the liver that mediates neutral lipid exchange between lipoprotein particles. The primary transfer:

• Cholesterol esters move from HDL → VLDL and LDL
• Triglycerides move from VLDL/LDL → HDL (in exchange)

The net effect of high CETP activity: HDL becomes triglyceride-rich and cholesterol-ester-poor → HDL particles are remodeled to smaller, denser forms → smaller HDL particles are cleared more rapidly by the kidney and liver → lower HDL-C in circulation. Simultaneously, LDL becomes enriched in cholesterol esters received from HDL → higher LDL-C.

This is why CETP inhibitors were developed as pharmaceutical HDL-raising agents. The logic was sound: reducing CETP activity would simultaneously raise HDL and lower LDL. The two leading candidates — torcetrapib and dalcetrapib — raised HDL dramatically but failed to reduce cardiovascular events in phase 3 trials, partly because of off-target effects (torcetrapib raised blood pressure), partly because raised HDL quantity without improved HDL function didn't translate to reduced atherosclerosis.

Anacetrapib succeeded (modestly reduced cardiovascular events in REVEAL trial 2017) — confirming that the CETP target is valid, but the magnitude of benefit is smaller than the lipoprotein changes predicted.

TaqIB and Coronary Heart Disease Risk

The rs708272 TaqIB variant has been studied extensively in the context of statin pharmacogenomics — specifically, whether statins benefit B1 and B2 individuals equally.

A landmark analysis from the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) by Ordovas et al. (2000) found that lovastatin reduced coronary events significantly in B1B1 individuals but not in B2B2 individuals. The explanation was mechanistically coherent: B2B2 individuals already had favorable lipid profiles (high HDL, lower CETP activity) that left less cardiovascular risk to modify. Their baseline risk was sufficiently low that statin-driven LDL reduction didn't add much further protection.

This finding highlights a broader principle: pharmacogenomics isn't just about drug metabolism (CYP enzymes) — it includes whether the target pathway is already at a favorable set point. B1B1 individuals have higher CETP activity, more unfavorable lipid exchange, and more room for statin benefit. B2B2 individuals may be in a "ceiling" zone where additional lipid modification provides diminishing returns.

Alcohol, CETP, and HDL: The Unusual Interaction

Moderate alcohol consumption is one of the most robustly documented HDL-raising interventions in epidemiology — and the mechanism is partly CETP-mediated. Alcohol reduces CETP mRNA expression and CETP mass in plasma. This is one reason why moderate wine drinkers consistently have higher HDL in population studies.

The CETP genotype modifies this alcohol-HDL effect substantially. A study by Gudnason et al. found that the HDL-raising effect of moderate alcohol was significantly larger in B1B1 individuals — the ones who start with high CETP activity and have the most room for CETP-mediated HDL suppression to be relieved. B2B2 individuals (already low CETP activity, high HDL) see less additional HDL increase from alcohol.

This does not, of course, argue for alcohol consumption as a cardiovascular intervention. The multiple harms of alcohol — liver, cancer, addiction, neurological — substantially outweigh the CETP-mediated HDL effect for most individuals. The finding is mechanistically interesting but not clinically actionable as a recommendation.

References